Lasmiditan
| Clinical data | |
|---|---|
| Pronunciation | /læzˈmɪdɪtæn/ laz-MID-i-tan |
| Trade names | Reyvow, Rayvow |
| Other names | COL-144; COL144; LY-573144; LY573144 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620015 |
| License data |
|
| Routes of administration | By mouth, intravenous |
| Drug class | Serotonin 5-HT1F receptor agonist; Antimigraine agent |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H18F3N3O2 |
| Molar mass | 377.367 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Lasmiditan, sold under the brand name Reyvow, is a medication used to treat migraines. It is not useful for prevention. The drug is taken by mouth.
Common side effects include sleepiness, dizziness, tiredness, and numbness.
Lasmiditan was approved in the United States in October 2019 and became available in February 2020. It was developed by Eli Lilly. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Lasmiditan is a Schedule V controlled substance in the United States.
In August 2026, the FDA withdrew approval of Reyvow at the request of Eli Lilly after the company notified the agency that the drug was no longer marketed.